
Currently out of the existing stock ratings of Charles Zhu, 28 are a BUY (90.32%), 3 are a HOLD (9.68%).
Analyst Charles Zhu, currently employed at GUGGENHEIM, has had 63.89% of price targets met with an average potential upside of 54.29%, reached in 340 days on average. Previously, Charles Zhu worked at LIFESCI.
Charles Zhu has documented 59 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MRUS, Merus BV at 30-Sep-2025.
Analyst best performing recommendations are on MGNX (MACROGENICS).
The best stock recommendation documented was for MGNX (MACROGENICS) on 1/2/2024. The price target of $20 was fulfilled within 62 days with a profit of $9.82 (96.46%), with a performance score of 15.56.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 13-Sep-2021
$3
$5
1 years 23 days ago
(28-Oct-2025)
0/19 (0%)
$1.21 (67.60%)
Buy Since 25-Sep-2023
$3
$4
1 years 10 months 10 days ago
(10-Jan-2025)
4/17 (23.53%)
$1.62 (117.39%)
9
Buy Since 28-Jun-2021
$38
1 years 11 months 7 days ago
(13-Dec-2024)
0/3 (0%)
$25.33 (199.92%)
Buy Since 14-Jul-2020
$25
$25
2 years 1 months 19 days ago
(01-Oct-2024)
2/9 (22.22%)
$21.53 (620.46%)
141
Buy Since 17-Mar-2022
$28
$43
3 years 6 months 10 days ago
(10-May-2023)
0/2 (0%)
$17.42 (164.65%)
What Year was the first public recommendation made by Charles Zhu?